Salt Lake City, UT, United States
Salt Lake City, UT, United States
SEARCH FILTERS
Time filter
Source Type

The present invention relates generally to genetic markers for duplication and/or deletion syndromes, such as Wolf-Hirschhorn syndrome (WHS), in particular to copy number variant genetic markers for selecting a patient for therapy for the particular therapy, or predicting the response of a subject to a particular therapy.


Patent
Lineagen and University of Utah | Date: 2016-07-15

The present disclosure relates to the identification of a subject that is affected with, or predisposed to, autism or to one or more autism spectrum disorders (ASD). The present disclosure includes methods related to the association of certain genetic markers with autism and/or ASD. More particularly, the present disclosure is related to methods and diagnostic tests for diagnosing or predicting ASD in an individual.


Patent
Lineagen | Date: 2014-12-22

Methods and compositions for the detection of single nucleotide polymorphisms (SNP) to determine whether the subject has autism spectrum disorder (ASD), is likely to develop ASD, or to classify a subject as having a particular ASD subtype. The presence and/or absence of the one or more SNPs is compared to the presence and/or absence of the SNPs in at least one sample training set(s), where the comparing step comprises applying a statistical algorithm which comprises determining a correlation between the SNP data obtained from the sample and the SNP data from the at least one training set.


The present invention relates generally to genetic markers for duplication and/or deletion syndromes, such as Wolf-Hirschhorn syndrome (WHS), in particular to copy number variant genetic markers for selecting a patient for therapy for the particular therapy, or predicting the response of a subject to a particular therapy.


Patent
Lineagen | Date: 2017-04-19

The present invention relates to methods of detecting differentially expressed protein expression indicative of COPD in a test sample. The detection of circulating levels of proteins within an identified COPD biomarker signature can aid in COPD diagnosis and disease monitoring, as well as in the prediction of responses to therapeutics. Evaluation of the biomarker signatures disclosed, or a subset of biomarkers thereof, provides a level of discrimination not found with individual markers.


News Article | November 3, 2016
Site: globenewswire.com

LEHI, Utah and SAN FRANCISCO, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Ancestry, the global leader in family history and consumer genomics, today announced three new appointments to its growing leadership team. As the world’s largest consumer genomics provider, having genotyped 2.5 million DNA samples, Ancestry is continuing to add to its roster of talent as it seeks to help millions of consumers better understand themselves and the world around them by unlocking the secrets hidden in their genes. “Amy, Sarah and Todd are joining in three roles that will have immense impact for Ancestry as we’re focused on continuing to provide powerful insights to our community and they more than live up to the best of the best we strive for when bringing on new talent,” said Tim Sullivan, chief executive officer of Ancestry. “We are struck daily by how the insights we provide can powerfully reshape someone’s understanding of who they are and how they fit into the bigger puzzle of our species. We’re excited to have Amy, Sarah and Todd help us focus on bringing new insights, products and growth.” Gershkoff, South and Davis bring incredible track records in their respective fields, and will help Ancestry continue to grow and innovate while providing consumers unmatched insights into their identities derived from the Company’s unique combination of genomic and genealogical data. Amy Gershkoff was most recently the chief data officer at Zynga, a pioneer in social gaming. Previously, she built and led the Customer Analytics & Insights team and led the Global Data Science team at eBay. Before eBay, Gershkoff was the chief data scientist for WPP, Data Alliance, where she worked across WPP’s more than 350 operating companies worldwide to create integrated data and technology solutions. As the head of media planning at Obama for America for the 2012 campaign, she architected Obama’s advertising strategy and designed the campaign's analytics systems. Her work has brought numerous accolades, including being featured in The Washington Post as one of the nation’s most prominent innovators and being named one of the “Top 50 Women to Watch in Tech” and one of San Francisco's Most Influential Women in Business by the San Francisco Business TImes. She holds a Ph.D. from Princeton University. Prior to joining Ancestry, Sarah South was the vice president of Laboratory Services at 23andme. She is certified in clinical cytogenetics by the American Board of Medical Genetics and Genomics (ABMGG). Previously, South was associate professor in the Department of Pathology at the University of Utah. She also served as a medical director at ARUP Laboratories and oversaw the Cytogenetic and Genomic Microarray Laboratories and directed the ABMGG clinical cytogenetics training program at the University of Utah. Sarah has also been the CLIA lab director for Lineagen. Her industry associations include, vice-chair of the American College of Medical Genetics Quality Assurance Committee; a member of the Clinical Laboratory Standards Institute Expert Panel for Molecular Methodologies and the ClinGen variant classification workgroup; a certified College of American Pathology Laboratory Inspector, and president of the American Cytogenetics Association. South also serves as an associate editor for the American Journal of Medical Genetics. She received her Ph.D. from the Johns Hopkins School of Medicine in Human Genetics, and completed a postdoctoral research fellowship in prenatal genetics at the Johns Hopkins Hospital, and a clinical cytogenetics fellowship at the University of Utah. Todd Davis joins Ancestry from Dropbox, where he led global talent acquisition. Prior to Dropbox, Davis spent four years leading Amazon’s global efforts to find and recruit across the company. Before joining Amazon in 2012, Davis was vice president, worldwide recruitment at Warner Bros. Entertainment, where he led efforts to improve global recruitment and talent acquisition resources by leveraging "best practices" in talent assessment and selection. He has also held senior positions at Centene Corporation, West Coast University and Volt Information Sciences. Davis is a board member of CASY and MSCCN and holds a Bachelor of Science from the University of New Hampshire. Ancestry, the global leader in family history and consumer genomics, harnesses the information found in family trees, historical records, and DNA to help people gain a new level of understanding about their lives. Ancestry has more than 2.4 million paying subscribers across its core Ancestry websites and more than 2.5 million DNA samples in the AncestryDNA database. Since 1996, more than 19 billion records have been added, and users have created more than 80 million family trees on the Ancestry flagship site and its affiliated international websites. Ancestry offers a suite of family history products and services including AncestryDNA, Archives, ProGenealogists, Newspapers.com and Fold3.


Patent
Lineagen and University of Utah | Date: 2013-11-06

Disclosed herein are methods and compositions for diagnosing multiple sclerosis (MS) in a subject or the risk of MS in a subject. More particularly, methods and compositions for the use of genetic markers for diagnosing MS in subject or the risk of MS in a subject.


Patent
University of Utah and Lineagen | Date: 2016-01-06

The present disclosure relates to the identification of a subject that is affected with, or predisposed to, autism or to one or more autism spectrum disorders (ASD). The present disclosure includes methods related to the association of certain genetic markers with autism and/or ASD. More particularly, the present disclosure is related to methods and diagnostic tests for diagnosing or predicting ASD in an individual.


News Article | July 28, 2015
Site: www.prweb.com

Center for Autism and Related Disorders (CARD) today announced that it will partner with Autism Research Group (ARG), Autism Care and Treatment Today! (ACT Today!) and Lineagen Delayed Development Testing Clinic to host an event that will offer families access to critical autism resources. The event is open to all families and will run from 9:00 a.m. to 5:00 p.m. on Saturday, Aug. 1, 2015 at the San Diego Marriott Del Mar’s Rancho Santa Fe Ballroom, located at 11966 El Camino Real, San Diego, Calif. 92130. Presentations will cover topics, such as: autism treatment options; how to handle challenging behaviors; how to apply for a financial grant; and information on genetic testing for individuals with autism. Genetic testing for children will be available on site using a painless cheek swab. The results will help pinpoint genetic causes for delayed development, including autism spectrum disorder (ASD). Registration is mandatory and child-friendly activities will be provided. “How to manage challenging behaviors in children with autism is a question that many parents have,” said CARD director of clinical quality, Sienna Greener-Wooten, PhD, BCBA. “We are eager to give families advice on the subject and excited to offer families access to all these wonderful resources in one place.” In addition to the presentation by CARD on applied behavior analysis (ABA) therapy and addressing challenging behaviors, ACT Today! will talk to families about grant opportunities and discuss the application process. Lineagen Delayed Development Testing Clinic will present on understanding the role of genetics in a disorder such as ASD and will administer the testing. The genetic test, Lineagen FirstStepDx Plus chromosomal microarray (CMA), has more extensive genetic content and provides a higher performance with twice the detection rate for genetic variations associated with ASD as compared to other available tests. Genetic testing can help families understand the “recurrence risk,” or the potential that this condition could occur again to another child in the family. To register for the morning testing group between 9:00 a.m. and noon, visit http://tinyurl.com/nnozmd6. To register for the afternoon testing group between 1:00 and 5:00 p.m., visit http://tinyurl.com/nca62a2. During registration, parents will be asked if they want their child to be swabbed and then an appointment will be made. At the swab appointments, children will be evaluated by a doctor and then cheek swabbed, with test results provided in about four to six weeks. Genetic testing for delayed development is usually covered by insurance, however any out-of-pocket cost for the test is guaranteed in writing before the test is done. Parents should bring their insurance card and have the most recent medical records for their child, particularly any diagnosis for delayed development, ASD or intellectual disability. Parents that have their children tested will have access to genetic counseling before and after the test and a detailed, but easy-to-read report on the results of the test. About Center for Autism and Related Disorders (CARD) CARD treats individuals of all ages who are diagnosed with autism spectrum disorder (ASD) at treatment centers around the globe. CARD was founded in 1990 by leading autism expert and clinical psychologist Doreen Granpeesheh, PhD, BCBA-D. CARD treats individuals with ASD using the principles of applied behavior analysis (ABA), which is empirically proven to be the most effective method for treating individuals with ASD and recommended by the American Academy of Pediatrics and the US Surgeon General. CARD employs a dedicated team of nearly 2,000 individuals across the nation and internationally. For more information, visit http://www.centerforautism.com or call (855) 345-2273. About Lineagen Based in Salt Lake City, Utah, Lineagen's mission is to accelerate and enhance the diagnostic evaluation of medical conditions so that the best possible outcomes can be achieved for patients and their families. Our first commercial offering, FirstStepDx PLUS, provides physicians with a fully integrated genetic testing, counseling and developmental screening service to aid in the diagnostic evaluation of individuals with autism spectrum disorder (ASD) or other disorders of childhood development. In addition to our deep commitment to ASD and developmental delay, we have ongoing scientific programs in the areas of multiple sclerosis (MS) and chronic obstructive pulmonary disease (COPD). For additional information, please visit http://www.lineagen.com. About Autism Care and Treatment Today! (ACT Today!) ACT Today! is a 501(c)3 non-profit organization dedicated to providing resources and funding to families of children with autism who cannot afford or access the necessary tools their children need to reach their full potential. For more information about ACT Today!, visit http://www.act-today.org. About ACT Today! for Military Families ACT Today! for Military Families (ATMF) is a national program of ACT Today!. ATMF works to improve awareness and delivery of effective autism services, and provides financial assistance to military families to help defray out-of-pocket costs associated with autism treatments, services and other quality of life programs. For more information about ATMF, visit http://www.acttodayformilitaryfamilies.org. About Autism Research Group (ARG) ARG is dedicated to identifying, evaluating and disseminating treatments that make a real, measurable difference in the lives of individuals with autism spectrum disorder (ASD) and their families. Founded in 2011 by a core group of autism research scientists who are dedicated to cultivating an autism-friendly world through cutting-edge treatment research, ARG uses science to improve the quality of life for people with ASD and the families who love them. The mission of ARG is to create a world that meets the treatment needs of individuals with ASD and their families through scientific research that is judiciously initiated, rigorously evaluated and effectively disseminated. For more information about ARG, visit http://www.autismresearchgroup.org.


The present invention relates generally to genetic markers for autism spectrum disorders and other childhood developmental delay disorders, in particular to copy number variant genetic markers for autism spectrum disorders.

Loading Lineagen collaborators
Loading Lineagen collaborators